Hospira Assumes Responsibility For Recent Abbott Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
Abbott spin-off Hospira will be accountable for resolving FDA quality oversight and manufacturing concerns related to the firm's intravenous administration sets
You may also be interested in...
Hospira Likely Will Revisit 2004 Guidance At End Of Summer Season
Hospira is maintaining its "conservative" top-line guidance for the 2004 second half - at least in the eyes of some Wall Street onlookers - due to an expected slowdown in hospital product sales this summer
Hospira Likely Will Revisit 2004 Guidance At End Of Summer Season
Hospira is maintaining its "conservative" top-line guidance for the 2004 second half - at least in the eyes of some Wall Street onlookers - due to an expected slowdown in hospital product sales this summer
Diabetes Care Growth Prospects Detailed By Abbott; Prism In Sight
Abbott's diabetes care unit will develop into a $1 bil. business within the next two years, according to VP-Investor Relations John Thomas